J Tabernero

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. ncbi request reprint XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
    Jim Cassidy
    CRC Department of Oncology, University of Glasgow, Garscube Estate, Bearsden, Glasgow G61 1DB, United Kingdom
    J Clin Oncol 22:2084-91. 2004
  2. ncbi request reprint Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 25:5225-32. 2007
  3. ncbi request reprint Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs
    A Hidalgo
    Radiology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Abdom Imaging 30:65-8. 2005
  4. doi request reprint Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, corrected Barcelona, Spain
    J Clin Oncol 26:1603-10. 2008
  5. doi request reprint Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035, Barcelona, Spain
    Oncologist 13:113-9. 2008
  6. doi request reprint Genomic medicine frontier in human solid tumors: prospects and challenges
    Rodrigo Dienstmann
    Vall d Hebron University Hospital, P Vall d Hebron 119 122, Barcelona, Spain 08035
    J Clin Oncol 31:1874-84. 2013
  7. ncbi request reprint Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mol Cancer Ther 11:2062-71. 2012
  8. ncbi request reprint Application of monoclonal antibodies as cancer therapy in solid tumors
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Curr Clin Pharmacol 7:137-45. 2012
  9. doi request reprint Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 28:1181-9. 2010
  10. pmc Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Oncologist 16:1729-40. 2011

Collaborators

Detail Information

Publications75

  1. ncbi request reprint XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
    Jim Cassidy
    CRC Department of Oncology, University of Glasgow, Garscube Estate, Bearsden, Glasgow G61 1DB, United Kingdom
    J Clin Oncol 22:2084-91. 2004
    ..The present studies further characterize efficacy and safety of the XELOX regimen...
  2. ncbi request reprint Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 25:5225-32. 2007
    ....
  3. ncbi request reprint Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs
    A Hidalgo
    Radiology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Abdom Imaging 30:65-8. 2005
    ..We found serial liver biopsies using Tru-Cut to be a safe and easy procedure. In our series, we could evaluate samples for molecular changes that influence the optimal dose, sequence, and schedule of the new antineoplastic agents...
  4. doi request reprint Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, corrected Barcelona, Spain
    J Clin Oncol 26:1603-10. 2008
    ..In order to identify a rationally based dose and schedule for cancer treatment, we have conducted a tumor pharmacodynamic phase I study in patients with advanced solid tumors...
  5. doi request reprint Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035, Barcelona, Spain
    Oncologist 13:113-9. 2008
    ....
  6. doi request reprint Genomic medicine frontier in human solid tumors: prospects and challenges
    Rodrigo Dienstmann
    Vall d Hebron University Hospital, P Vall d Hebron 119 122, Barcelona, Spain 08035
    J Clin Oncol 31:1874-84. 2013
    ....
  7. ncbi request reprint Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mol Cancer Ther 11:2062-71. 2012
    ..2%). These results suggest that matching chemorefractory patients with colorectal cancer with targeted agents in phase I trials based on the current molecular profile does not confer a significant clinical benefit...
  8. ncbi request reprint Application of monoclonal antibodies as cancer therapy in solid tumors
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Curr Clin Pharmacol 7:137-45. 2012
    ..Here we provide an overview of monoclonal antibodies approved for use in clinical oncology and those currently in clinical development...
  9. doi request reprint Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 28:1181-9. 2010
    ....
  10. pmc Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Oncologist 16:1729-40. 2011
    ..Ultimately, the predictive value of a side effect of molecular targeted therapies requires validation in prospective trials...
  11. ncbi request reprint The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents
    Josep Tabernero
    Medical Oncology Service, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Mol Cancer Res 5:203-20. 2007
    ..The potential of this novel approach to anticancer therapy will be elucidated by large, ongoing clinical trials...
  12. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain corrected
    J Clin Oncol 23:2521-33. 2005
    ....
  13. ncbi request reprint Novel targeted therapies in the treatment of gastric and esophageal cancer
    J Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 16:1740-8. 2005
    ..The emerging data from the clinical development of these compounds has provided novel opportunities in the treatment of EC and GC that will probably translate into efficacy advantage in the treatment of these common malignancies...
  14. doi request reprint Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
    J Tabernero
    Medical Oncology Service, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Oncol 21:1537-45. 2010
    ....
  15. doi request reprint Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors
    R Salazar
    Instituto Catalán de Oncología, Ctra Gran Vía, 08907 s n L Hospitalet de Llobregat, Barcelona, Spain
    Cancer Chemother Pharmacol 72:75-83. 2013
    ..This dose-escalating phase I clinical trial evaluated the maximum tolerated dose (MTD), and the recommended dose for further phase II studies (RD) of weekly KF given as a prolonged (3- to 24-h) intravenous (i.v.) infusion...
  16. ncbi request reprint Monoclonal antibodies in the treatment of advanced colorectal cancer
    J Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron 119 129, 08035 Barcelona, Spain
    Eur J Surg Oncol 33:S24-34. 2007
    ..There is a need to optimize and define the best use of these new approaches. In this review, the authors examine the current development status of monoclonal antibodies in the treatment of advanced colorectal cancer...
  17. ncbi request reprint Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy)
    E Aranda
    Medical Oncology Service, Hospital Universitario Reina Sofia, Cordoba, Spain
    Clin Transl Oncol 8:98-102. 2006
    ....
  18. doi request reprint Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours
    E Elez
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 19:vii146-52. 2008
  19. doi request reprint Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
    B Markman
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Oncol 23:2399-408. 2012
    ....
  20. ncbi request reprint Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer
    Teresa Macarulla
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Onkologie 29:99-105. 2006
    ..In this review we describe the current status of therapeutic strategies based on EGFR inhibitors in the treatment of GI cancer...
  21. ncbi request reprint Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study
    Albert Abad
    Institut Catala Oncologia, Servicio de Oncologia Medica, Hospital Germans Trias i Pujol, Barcelona Cta Canyet s n, Barcelona, Spain
    Acta Oncol 47:286-92. 2008
    ....
  22. pmc Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines
    E Vilar
    Department of Medical Oncology and Laboratory of Oncology Research, Vall d Hebron University Hospital, Barcelona, Spain
    Br J Cancer 99:1607-12. 2008
    ..Mutation of MRE11 and RAD50 could account for this difference in response to CPT-11. Future clinical trials tailoring chemotherapy regimens based on microsatellite status are warranted...
  23. ncbi request reprint Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy
    M Martin-Richard
    ICMHO, Servicio de Oncologia Medica, Hospital Clinic de Barcelona, Barcelona, Spain
    Oncology 66:388-94. 2004
    ..In parallel, HER2, which is commonly coexpressed with Topo II, and p53, a modulator of chemotherapy activity, were also analyzed...
  24. ncbi request reprint Targeted therapy in advanced colon cancer: the role of new therapies
    J Tabernero
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 15:iv55-62. 2004
  25. ncbi request reprint Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer
    Rodrigo Dienstmann
    Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Medical Oncology Department, Passeig Vall d Hebron 119 129, Barcelona, Spain
    Curr Opin Investig Drugs 11:1434-41. 2010
    ..Success in the ongoing phase III clinical trials in patients with advanced NSCLC would lead to necitumumab becoming a valuable addition to future therapeutic strategies in oncology...
  26. ncbi request reprint Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
    Federico Rojo
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 24:4309-16. 2006
    ..The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study...
  27. doi request reprint Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment
    Higinio Dopeso
    Group of Molecular Oncology, Molecular Biology and Biochemistry Research Center, CIBBIM Nanomedicine, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 16:2375-82. 2010
    ..However, only 20% to 30% of patients show an objective response to irinotecan, and there is great need for new molecular markers capable of identifying the subset of patients who are unlikely to respond...
  28. ncbi request reprint Monoclonal antibodies in solid tumours
    Ben Markman
    Medical Oncology Service, Vall d Hebron University Hospital, P Vall d Hebron, Barcelona, Spain
    Curr Clin Pharmacol 5:160-5. 2010
    ..In this commentary we review those mAbs now in routine use for solid tumours, interesting aspects of their use and future directions...
  29. doi request reprint Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
    C Serrano
    Breast Cancer Center, Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 23:897-902. 2012
    ..Elderly breast cancer patients are usually excluded from clinical trials. Nevertheless, with the increasing use of trastuzumab, there is a need to address trastuzumab-related cardiotoxicity in this population...
  30. ncbi request reprint A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
    J Tabernero
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 15:1358-65. 2004
    ..A phase II randomised trial was conducted to evaluate the tolerability and activity of weekly or 3-weekly docetaxel in patients with metastatic breast cancer...
  31. doi request reprint A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
    J Capdevila
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Pg Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Cancer Chemother Pharmacol 71:1247-54. 2013
    ..v.) infusion every 3 weeks (q3wk)...
  32. doi request reprint Biomarkers in colorectal cancer
    B Markman
    Medical Oncology Department, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Barcelona, Spain
    Clin Transl Oncol 12:261-70. 2010
    ..The identification and implementation of validated biomarkers has the potential to further our understanding of the biology of colorectal cancer and also to greatly improve the efficiency with which cancer treatments are administered...
  33. doi request reprint Status of PI3K inhibition and biomarker development in cancer therapeutics
    B Markman
    Medical Oncology Service, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Oncol 21:683-91. 2010
    ..A new generation of PI3K inhibitors is now entering early clinical trials, with much anticipation that they will add to the growing armamentarium of targeted cancer therapeutics...
  34. doi request reprint Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer
    Teresa Macarulla
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Colorectal Cancer 7:300-8. 2008
    ..Also, preliminary data suggest that cetuximab can be administered in a more convenient 2-week schedule in combination with standard chemotherapy...
  35. ncbi request reprint Oxaliplatin-based chemotherapy in the management of colorectal cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Expert Rev Anticancer Ther 8:1223-36. 2008
    ..In this review, the authors examine the development of oxaliplatin as well as the main trials that have positioned oxaliplatin as a key drug in the treatment of CRC...
  36. doi request reprint Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors
    Beatriz Pardo
    Institut Català d Oncologia and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 14:1116-23. 2008
    ....
  37. ncbi request reprint New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era
    Jaume Capdevila
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Discov Med 9:153-62. 2010
    ..Moreover, the encouraging initial results of first clinical trials have accelerated the development of placebo-controlled phase III studies that will assess the role of these new agents in the management of differentiated thyroid cancer...
  38. doi request reprint Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Treat Rev 35:354-63. 2009
    ..In this review, the authors examine the development of monoclonal antibodies against EGFR and the effects of this blockage in cell cycle, as well as the most important trials with these monoclonal antibodies in several tumor types...
  39. ncbi request reprint New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era
    Jaume Capdevila
    Vall d Hebron University Hospital, Medical Oncology Department, Barcelona, Spain
    Expert Rev Anticancer Ther 7:1027-41. 2007
    ..In this review, the authors examine the most important trials with monoclonal antibodies and tyrosine kinase inhibitors in the treatment of advanced colorectal cancer...
  40. ncbi request reprint Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona 08035, Spain
    Endocr Relat Cancer 14:221-32. 2007
    ..Also a comprehensive review of the literature about chemotherapy in NETs is presented...
  41. doi request reprint Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers
    Jaume Capdevila
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Curr Opin Oncol 21:374-80. 2009
    ..The increasing development of new targeted therapies in human cancer has also impacted in these rare gastrointestinal malignancies providing a wide range of possibilities in the design of future clinical trials...
  42. ncbi request reprint EGFR and KRAS in colorectal cancer
    Ben Markman
    Medical Oncology Department, Vall d Hebron Institute of Oncology VHIO, Vall d Hebron University Hospital, Barcelona, Spain
    Adv Clin Chem 51:71-119. 2010
    ....
  43. ncbi request reprint Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: a phase II study
    Jordi Giralt
    Department of Radiation Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Radiother Oncol 89:263-9. 2008
    ....
  44. doi request reprint Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma
    Fernando Rivera
    Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain
    Int J Radiat Oncol Biol Phys 75:1430-6. 2009
    ....
  45. ncbi request reprint PELO negatively regulates HER receptor signalling and metastasis
    K Pedersen
    Preclinical Research Program, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Oncogene 33:1190-7. 2014
    ..These results reveal that PELO is a novel regulator of HER-signalling and therefore is likely to have a role in inhibiting tumour progression and invasion. ..
  46. ncbi request reprint New drugs and new approaches in metastatic bladder cancer
    J Bellmunt
    Hospital General Universitari Vall d Hebron, P Vall d Hebron 119 129, 08035 Barcelona, Spain
    Crit Rev Oncol Hematol 47:195-206. 2003
    ....
  47. doi request reprint Targeted therapies in thyroid cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron 119 129, 08035, Barcelona, Spain
    Target Oncol 4:275-85. 2009
    ..The development of new, targeted therapies and their encouraging initial results have opened a hopeful opportunity of treatment for these orphan therapy tumor patients...
  48. doi request reprint Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms
    Albert Font
    Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Crta Canyet s n, 08916, Badalona, Barcelona, Spain
    Cancer Chemother Pharmacol 62:1075-83. 2008
    ....
  49. ncbi request reprint Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy
    César Serrano
    Medical Oncology Department, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Cancer J 16:226-34. 2010
    ..This topic review will focus on the molecular basis and the mechanisms of action of epidermal growth factor receptor inhibitors, the clinical trials in this field and future trends of such compounds in CRC...
  50. doi request reprint Cardiotoxicity
    I Brana
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 21:vii173-9. 2010
    ..It also emphasizes the importance of early detection and correction of cardiovascular risk factors and the relevance of close cardiac monitoring during antineoplastic treatment in order to reduce cardiotoxicity...
  51. ncbi request reprint Molecular biology of testicular germ cell tumors
    E Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Transl Oncol 8:846-50. 2006
    ..This review summarizes the current knowledge in the field of molecular biology of TGCT...
  52. ncbi request reprint Novel targets for anticancer treatment development in colorectal cancer
    Teresa Macarulla
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Colorectal Cancer 6:265-72. 2006
    ..In this article, we review the current developmental status of some of the most advanced targeted therapies in the treatment of CRC...
  53. ncbi request reprint Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer
    Francisco Javier Ramos
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Colorectal Cancer 7:S52-7. 2008
    ..K-ras mutation analysis may now be considered a new standard of care in the selection of patients for EGFR-targeted therapy...
  54. ncbi request reprint Novel targets in gastric and esophageal cancer
    Claudia María Valverde
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, Barcelona, Spain
    Crit Rev Oncol Hematol 59:128-38. 2006
    ..The emerging data from the clinical development of these compounds has provided novel opportunities in the treatment of EC and GC that will probably translate into clinical benefit for patients with these common malignancies...
  55. ncbi request reprint [Value of inhibition of signal transduction and epigenetic therapy concepts in cancer therapy]
    Josep Tabernero
    Vall d Hebron University Hospital, Medical Oncology Service, Barcelona, Spain
    Onkologie 28:43-7. 2005
  56. ncbi request reprint Aurora kinase family: a new target for anticancer drug
    Teresa Macarulla
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Recent Pat Anticancer Drug Discov 3:114-22. 2008
    ..This review focuses in recent progress in the role of AK in tumorogenesis and the development of new anticancer drug against AK proteins. This manuscript also includes some relevant patents as well...
  57. ncbi request reprint Current issues in adjuvant treatment of stage II colon cancer
    Thierry Andre
    Service d Oncologie Medicale, Hopital Tenon, 4 rue de la Chine, 75970, Paris Cedex 20, France, and Vall d Hebron University Hospital, Barcelona, Spain
    Ann Surg Oncol 13:887-98. 2006
    ..In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial...
  58. doi request reprint The role of salvage treatment in advanced colorectal cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron 119 129, 08035 Barcelona, Spain
    Crit Rev Oncol Hematol 71:53-61. 2009
    ..With the possibility of active salvage therapy, surgery rescue approaches should be taken in account during all the course of the patients' disease...
  59. doi request reprint Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
    Luis G Paz-Ares
    Instituto de Biomedicina de Sevilla and Hospital Universitario Virgen del Rocio, Seville, Spain
    J Clin Oncol 29:3783-90. 2011
    ....
  60. ncbi request reprint BRAF as a target for cancer therapy
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Spain
    Anticancer Agents Med Chem 11:285-95. 2011
    ....
  61. ncbi request reprint Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2
    Rodrigo Dienstmann
    Medical Oncology Service, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, 08035, Spain
    Recent Pat Anticancer Drug Discov 6:210-36. 2011
    ..This review will focus primarily on an analysis of newly developed inhibitors of this pathway that have entered clinical trials, and recently registered patents in this field...
  62. ncbi request reprint Management and outcomes in digestive cancer surgery: design and initial results of a multicenter cohort study
    M Espallargues
    Catalan Agency for Health Technology Assessment and Research, Carrer de Roc Boronat 81 95, Barcelona, Spain
    Rev Esp Enferm Dig 101:680-96. 2009
    ..most studies that analyze the influence of structure factors on clinical outcomes are retrospective, based on clinical-administrative databases, and mainly focusing on surgical volume...
  63. ncbi request reprint Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Thierry Andre
    Hopital Tenon, Paris
    N Engl J Med 350:2343-51. 2004
    ..Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting...
  64. ncbi request reprint The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies
    Siegfried Segaert
    Department of Dermatology, Katholieke Universiteit Leuven, Belgium
    J Dtsch Dermatol Ges 3:599-606. 2005
    ..Evidence-based studies are needed to determine the best way to manage these effects...
  65. ncbi request reprint Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients
    Hans Joachim Schmoll
    Martin Luther University, Halle, Germany
    J Clin Oncol 25:102-9. 2007
    ..To report the results of a planned safety analysis from a phase III trial comparing capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil/leucovorin (FU/LV) as adjuvant therapy for stage III colon cancer...
  66. doi request reprint Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
    Gunnar Folprecht
    Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
    Clin Cancer Res 14:215-23. 2008
    ..Complete pharmacokinetic sampling and tumor biopsies, when feasible, were conducted...
  67. ncbi request reprint Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet
    Jose Baselga
    J Clin Oncol 25:4516-8. 2007
  68. ncbi request reprint Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group
    Bernard Nordlinger
    Hopital Ambroise Pare, CHU Paris Ouest, 92100 Boulogne Cedex, France
    Eur J Cancer 43:2037-45. 2007
    ....
  69. ncbi request reprint Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer
    Eva Thomas
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 25:3399-406. 2007
    ..This international phase II trial assessed the activity of ixabepilone in patients with metastatic breast cancer (MBC) that was resistant to taxane therapy...
  70. ncbi request reprint Phase II study of trabectedin in pretreated patients with advanced colorectal cancer
    Luis Paz-Ares
    Medical Oncology Deparment, Hospital Universitario 12 de Octubre, Madrid, Spain
    Clin Colorectal Cancer 6:522-8. 2007
    ..This open-label, nonrandomized, phase II study was aimed at evaluating the efficacy and toxicity of trabectedin over a 3-hour intravenous infusion every 3 weeks in patients with pretreated advanced colorectal cancer...
  71. doi request reprint Potential regional differences for the tolerability profiles of fluoropyrimidines
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:2118-23. 2008
    ....
  72. ncbi request reprint Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities
    Josep Tabernero
    Onkologie 28:467-70. 2005
  73. ncbi request reprint Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors
    Eduardo Vilar
    Am J Clin Oncol 28:424. 2005
  74. pmc CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity
    Ron Firestein
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 455:547-51. 2008
    ..Together these observations suggest that therapeutic interventions targeting CDK8 may confer a clinical benefit in beta-catenin-driven malignancies...
  75. ncbi request reprint Cetuximab and chemotherapy for patients with unresectable CRC liver metastasis: are we changing the natural course of the disease?
    Francisco Javier Ramos
    Onkologie 30:602-4. 2007